161 related articles for article (PubMed ID: 34589976)
1. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Rocha P; Ramal D; Ripoll E; Moliner L; Corbera A; Hardy-Werbin M; Orrillo M; Taus Á; Zuccarino F; Gibert J; Perera-Bel J; Casadevall D; Arriola E
JTO Clin Res Rep; 2021 Jan; 2(1):100115. PubMed ID: 34589976
[TBL] [Abstract][Full Text] [Related]
2. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
4. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
[TBL] [Abstract][Full Text] [Related]
6. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
[TBL] [Abstract][Full Text] [Related]
7. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
Wang Z; Liu C; Bai Y; Zhao X; Cui L; Peng Z; Zhang X; Wang X; Zhao Z; Li J; Shen L
Front Oncol; 2021; 11():761110. PubMed ID: 34858840
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
9. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.
Wang X; Guo Z; Wu X; Chen D; Wang F; Yang L; Luo M; Wu S; Yang C; Huang L; Fu L
Immunotargets Ther; 2023; 12():1-16. PubMed ID: 36632330
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma.
Karabajakian A; Garrivier T; Crozes C; Gadot N; Blay JY; Bérard F; Céruse P; Zrounba P; Saintigny P; Mastier C; Fayette J
Oncotarget; 2020 May; 11(18):1618-1628. PubMed ID: 32405337
[No Abstract] [Full Text] [Related]
11. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
13. Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis.
Kim MJ; Hong SPD; Park Y; Chae YK
Cancer Med; 2024 Feb; 13(3):e6970. PubMed ID: 38400685
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
[TBL] [Abstract][Full Text] [Related]
18. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
